NET ASSET VALUE – 31 August 2026
NET ASSET VALUE – 31 August 2026
2026-09-02 08:00:00
On the 31 August 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,342 million and NAV per share was SEK 38.54. Return on NAV per share in the month was -1.8%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Lipum | 100% | 348 | 4.01 | 10.4% |
| Prokarium | 50% | 289 | 3.34 | 8.7% |
| Atrogi | 47% | 215 | 2.48 | 6.4% |
| KAHR Medical | 34% | 206 | 2.37 | 6.2% |
| Empros Pharma | 79% | 204 | 2.36 | 6.1% |
| Bonsai Biotherapeutics | 100% | 158 | 1.82 | 4.7% |
| Microbiotica | 10% | 130 | 1.50 | 3.9% |
| Mendus | 22% | 98 | 1.13 | 2.9% |
| Xintela | 60% | 85 | 0.98 | 2.5% |
| Xspray Pharma | 17% | 81 | 0.93 | 2.4% |
| AnaCardio | 13% | 79 | 0.92 | 2.4% |
| Geneos Therapeutics | 12% | 68 | 0.79 | 2.0% |
| EpiEndo Pharmaceuticals | 9% | 55 | 0.64 | 1.6% |
| Vitara Biomedical | 11% | 54 | 0.62 | 1.6% |
| Egetis Therapeutics | 1% | 38 | 0.44 | 1.2% |
| Buzzard Pharmaceuticals | 15% | 33 | 0.38 | 1.0% |
| Amarna Therapeutics | 58% | 11 | 0.13 | 0.3% |
| Strike Pharma | 18% | 11 | 0.12 | 0.3% |
| Total | 2,165 | 24.97 | 64.8% | |
| Commercial Growth | ||||
| Symcel | 30% | 211 | 2.43 | 6.3% |
| NorthX Biologics | 61% | 202 | 2.33 | 6.0% |
| Chromafora | 28% | 137 | 1.59 | 4.1% |
| Nanologica | 50% | 61 | 0.71 | 1.8% |
| Frontier Biosolutions | 2% | 27 | 0.31 | 0.8% |
| Bohus Biotech | 45% | 22 | 0.26 | 0.7% |
| Total | 661 | 7.62 | 19.8% | |
| Assets related to Portfolio companies | 223 | 2.57 | 6.7% | |
| Other assets and liabilities | 294 | 3.39 | 8.8% | |
| Net Asset Value | 3,342 | 38.54 | 100.0% | |